Should patient groups accept money from drug companies? NoBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39185.394005.AD (Published 03 May 2007) Cite this as: BMJ 2007;334:935
- Barbara Mintzes, research associate
- Therapeutics Initiative and Health Action International (HAI-Europe), 2176 Health Sciences Mall, Vancouver BC, V6T 1Z3 Canada
Patient groups provide information, advice, and support; represent patients on governmental committees; and speak in the media on behalf of patients. They can be a voice for someone who faces pain, invasive procedures, isolation, disability, and at times discrimination and poor medical care. However, a different view emerges in the pharmaceutical marketing literature, of “allies to help advance brand objectives”.1
Can patient groups provide impartial information and represent people who are ill if they are funded by companies that sell products to treat those illnesses? I believe that the conflict of interest inherent in such a relationship makes this difficult. For patients there are three key risks:
Disguised promotion channelled through a seemingly neutral third party
Confusion between patients' and sponsors' interests in policy of patient groups
Inadequate representation when those interests diverge.
How big is the problem?
Industry funding of patient groups is common. Ball et al examined websites of 69 patient groups for 10 chronic conditions; 37 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial